[Preoperative treatment with UFT for patients with ovarian malignant tumors].
A 300-mg dose of UFT was administered daily for seven days prior to surgery for ovarian malignant tumors. The concentrations of FT, 5-FU and uracil in the serum, tumor tissue, adjacent normal tissue and ascitic fluid were measured. The results were as follows: 5-FU concentration in the serum was 0.008 +/- 0.006 micrograms/ml (n = 14) and the concentration in the ascitic fluid was 0.008 +/- 0.006 micrograms/ml (n = 4). The 5-FU concentration in the tumor tissue was 0.142 +/- 0.199 micrograms/g. This was approximately 3.0 times higher than the concentration in the adjacent normal tissue which was 0.048 +/- 0.030 micrograms/g and the T/B ratio (formula; see text) was approximately 17.8.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000097:blood / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010053:Ovary / Q000378:metabolism; D011300:Preoperative Care; D005641:Tegafur / Q000378:metabolism / Q000627:therapeutic use; D014498:Uracil / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use
D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil